Viagra: A Success Story For Rationing?
Authors:
- Heidrun SturmHSHeidrun Sturm
- 1 November 2002
- journal article
- research article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 21 (6) , 177-181
Abstract
The 1998 launch of Viagra prompted widespread fears about the budgetary consequences for insurers and governments, all the more so since Viagra was only the first of a new wave of so-called lifestyle drugs. The fears have turned out to be greatly exaggerated. This paper analyzes the rationing strategies adopted in four countries (United States, Britain, Germany, and Sweden), relates them to the characteristics of different types of health care systems, and identifies the conditions necessary for successful cost containment. The case of Viagra, it concludes, holds out two general lessons: first, allow exceptions to total bans on reimbursement; second, involve the medical profession in the decision-making process.Keywords
This publication has 8 references indexed in Scilit:
- NICE: faster access to modern treatments? Analysis of guidance on health technologiesBMJ, 2001
- The failings of NICEBMJ, 2000
- Valuing the effects of sildenafil in erectile dysfunctionBMJ, 2000
- Cost utility analysis of sildenafil compared with papaverine-phentolamine injectionsBMJ, 2000
- The Economics Of ViagraHealth Affairs, 2000
- Viagra: a botched test case for rationingBMJ, 1999
- Muddling Through Elegantly: Finding The Proper Balance In RationingHealth Affairs, 1997
- THE EPIDEMIOLOGY OF ERECTILE DYSFUNCTIONUrologic Clinics of North America, 1995